This is a working overview of secretagogue, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-07. Anything still debated is marked as such rather than presented as settled.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
== Pharmaceutical manufacture == Calcitonin was extracted from the ultimobranchial glands (thyroid-like glands) of fish, particularly salmon. Salmon calcitonin resembles human calcitonin, but is more active. At present, it is produced either by recombinant DNA technology or by chemical peptide synthesis. The pharmacological properties of the synthetic and recombinant peptides have been demonstrated to be qualitatively and quantitatively equivalent.
=== Guest appearances === Snobs (13 January 2000) – 1 episode Loose Women (16 September 2011, 1 March 2012, 26 April 2013, 3 October 2013, 24 February 2014, 4 February 2016, 4 March 2016, 3 March 2017, 6 April 2017, 7 September 2017, 2 March 2018, 27 June 2018, 11 February 2019, 20 February 2019, 19 March 2019, 6 August 2020) – 16 episodes I'm a Celebrity...Get Me Out of Here! NOW! (23–25 November 2011, 16 November 2015) – 4 episodes Peter Andre: My Life (14 December 2011) – 1 episode That Sunday Night Show (8 January 2012) – 1 episode Celebrity Juice (15 March 2012, 9 May 2013, 11 April 2019, 24 October 2019, 12 November 2020) – 5 episodes This Morning (30 March 2012, 2 April 2012, 4 April 2012, 31 August 2012, 19 September 2012, 18 January 2013, 5 April 2013, 19 April 2013, 24 April 2013, 28 November 2014, 3 December 2014, 4 December 2014, 13 May 2015, 5 February 2016, 4 July 2016, 2 August 2016, 30 April 2018, 1 October 2018, 7 January 2019, 23 January 2019, 4 February 2019, 11 February 2019, 14 August 2019, 18 December 2019, 28 June 2024) – 25 episodes The Big Quiz (15 April 2012) – 1 episode 8 Out of 10 Cats (15 June 2012, 25 January 2013, 28 January 2020) – 3 episodes Big Brother's Bit on the Side (4 July 2012, 28 July 2013, 13 May 2015, 16 June 2017) – 4 episodes Let's Do Lunch with Gino & Mel (29 August 2012) – 1 episode Celebrity Big Brother's Bit on the Side (6 September 2012, 9 January 2013, 1 September 2013, 19 August 2014, 29 January 2015, 2 February 2016, 4–5 February 2016, 1 August 2017) – 9 episodes Fake Reaction (3 January 2013) – 1 episode 8 Out of 10 Cats Does Deal or No Deal (4 January 2013) – 1 episode Food Glorious Food (24 April 2013) – 1 episode Sunday Side Up (29 December 2013) – 1 episode Who's Doing the Dishes? (3 October 2014) – 1 episode Phillip's Live 24-Hour TV Marathon (1 December 2014) – 1 episode Mel & Sue (14 January 2015) – 1 episode If Katie Hopkins Ruled the World (6 August 2015) – 1 episode Kendra on Top (21 August 2015) – 1 episode Keep It in the Family (22 August 2015) – 1 episode Safeword (27 August 2015) – 1 episode Tina Malone: My New Body (1 October 2015) – 1 episode Tricked (27 October 2015) – 1 episode The Wright Stuff (4 February 2016) – 1 episode Virtually Famous (8 March 2016) – 1 episode In Therapy (5 July 2016) – 1 episode It's Not Me, It's You (29 July 2016) – 1 episode Sky News (25 October 2016, 6 September 2024) – 2 episodes Alan Carr's Specstacular (31 December 2016) – 1 episode Through the Keyhole (4 February 2017) – 1 episode BBC Radio 1 Teen Awards (22 October 2017, 21 October 2018) Celebrity 100% Hotter (25 January 2018) – 1 episode The Generation Game (1 April 2018) – 1 episode Livin' with Lucy (10 September 2018) – 1 episode ReFreshers Week Presented By Strongbow (1 October 2018) – 1 episode Your Face or Mine? (3 October 2018) – 1 episode Good Morning Britain (30 October 2018, 19 December 2018, 4 February 2019, 1 April 2019, 24 June 2019, 7 August 2019, 13 November 2019, 25 November 2019, 8 December 2020) – 9 episodes I'll Get This (4 December 2018) – 1 episode Lorraine (4 January 2019, 18 January 2019, 23 January 2019, 8 March 2019, 9 September 2019, 30 September 2019, 15 November 2019, 11 December 2023) – 8 episodes The Jonathan Ross Show (9 March 2019) – 1 episode The Real Housewives of Cheshire (22 April 2019, 11 November 2019) – 2 episodes The Crystal Maze (21 June 2019) – 1 episode Celebrity Catchphrase (31 August 2019) – 1 episode MTV Cribs UK (16 September 2019, 7 December 2020) – 2 episodes Dancing on Ice at Christmas (22 December 2019) – 1 episode The Big Narstie Show (7 February 2020) – 1 episode Inside Missguided: Made in Manchester (12 August 2020) – 1 episode Rolling In It (15 August 2020) – 1 episode Shopping with Keith Lemon (25 October 2020) – 1 episode Celebrity Supply Teacher (17 November 2020) – 1 episode The Wheel (19 December 2020, 18 December 2021) – 2 episodes Dancing on Ice (24 January 2021) – 1 episode Piers Morgan's Life Stories (11 February 2021) – 1 episode RuPaul's Drag Race UK (18 February 2021) – 1 episode Mel Giedroyc: Unforgivable (23 February 2021) – 1 episode Sophie Ellis-Bextor's Kitchen Disco Danceathon (16 November 2021) – 1 episode Angela Scanlon's Ask Me Anything (27 November 2021) – 1 episode The Weakest Link (23 December 2021) – 1 episode Celebrity MasterChef: Christmas Cook-Off (23 December 2021) – 1 episode The Travel Show (4 February 2022) – 1 episode Springwatch (8 June 2022) – 1 episode The Big Breakfast (20 August 2022, 27 August 2022, 3 September 2022) – 3 episodes The Great Scott TreadMills Challenge (16 November 2022) – 1 episode The Greatest Snowman (26 December 2022) – 1 episode Mwy Na Daffs a Taffs (2 March 2023) – 1 episode Would I Lie to You? (24 March 2023) – 1 episode The Great Stand Up to Cancer Bake Off (26 March 2023) – 1 episode Late Night Lycett (14 April 2023) – 1 episode Steph's Packed Lunch (16 May 2023) – 1 episode The Comedy Roast for SU2C (3 November 2023) – 1 episode Celebrity Antiques Road Trip (28 November 2023) – 1 episode Blankety Blank (23 December 2023) – 1 episode The Underdog: Josh Must Win (3 April 2024) – 1 episode Drama Queens (1 May 2024) – 1 episode Who Do You Think You Are? (26 September 2024) – 1 episode Katy Perry: Night of a Lifetime (21 December 2024) – 1 episode Pointless Celebrities (25 January 2025) – 1 episode ITV Racing: Cheltenham Festival Live (13 March 2025, 12 March 2026) – 2 episodes I'm a Celebrity: Unpacked (17 April 2026, 20 April 2026) – 2 episodes
=== Brand names === It is marketed under the brand name Rivotril by Roche in Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, Colombia, Costa Rica, Croatia, the Czech Republic, Denmark, Estonia, Germany, Hungary, Iceland, Ireland, Italy, China, Mexico, the Netherlands, Norway, Portugal, Peru, Pakistan, Romania, Serbia, South Africa, South Korea, Saudi Arabia, Spain, Turkey, and the United States; Emcloz, Linotril, Lonazep, Clotrin and Clonotril in India and other parts of Europe; under the name Riklona in Indonesia and Malaysia; and under the brand name Klonopin by Roche in the United States. Other names, such as Antelepsin, Clonoten, Ravotril, Rivotril, Iktorivil, Clonex (Israel), Paxam, Petril, Naze, Zilepam and Kriadex, are used throughout the world. In August 2021, Roche Australia transferred Rivotril to Pharmaco Australia Ltd.
Sources: en.wikipedia.org
==== Hardware wallets ==== A hardware "wallet" is a small and portable computer peripheral that signs transactions as requested by the user. These devices store private keys and carry out signing and encryption internally, and do not share any sensitive information with the host computer except already signed (and thus unalterable) transactions. Because hardware wallets never expose their private keys, even computers that may be compromised by malware do not have a vector to access or steal them.The user sets a passcode when setting up a hardware signer. As hardware signers are tamper-resistant, without the passcode the assets cannot be accessed.
Pio's case demonstrated that stigmatization provided proofs for believers, but equally for skeptics as it offered evidence to indicate deception was involved in the alleged miracle. Responses to his stigmata embodied polarized views, some held him to be the perfect human being, while others a fraud whose wounds are not a result of devotion, but carbolic acid. Throughout his life, Pio had hidden his wounds by wearing fingerless gloves. At death there were no wounds, only "unblemished skin". Giacomo Piccirillo the friar commissioned to photograph the deceased body, said on the left palm he saw a small scar and physical residual marks, as if it were a scarred wound that had healed some time ago. Padre Pio had also copied the words of the Italian mystic and stigmatic Gemma Galgani in his spiritual letters, and may have attempted to divert suspicion of his use of her work.
as shown above for one decay. The solution can be found by the integration factor method, where the integrating factor is eλBt. This case is perhaps the most useful since it can derive both the one-decay equation (above) and the equation for multi-decay chains (below) more directly.
=== Function === PNECs may play a role with chemoreceptors in hypoxia detection. This is best supported by the presence of an oxygen-sensitive potassium channel coupled to an oxygen sensory protein in the rabbit lumenal membrane. They are hypothetically involved in regulating localized epithelial cell growth and regeneration through a paracrine mechanism, whereby their signaling peptides are released into the environment. In addition, they contain neuroactive substances which are released from basal cytoplasm. These substances induce autonomic nerve terminals or vasculature in the deep lamina propria.
Sources: en.wikipedia.org
== Applications == There are numerous applications for quantitative polymerase chain reaction in the laboratory. It is commonly used for both diagnostic and basic research. Uses of the technique in industry include the quantification of microbial load in foods or on vegetable matter, the detection of GMOs (genetically modified organisms) and the quantification and genotyping of human viral pathogens.
Jaquelyn Patricia Longworth, Operational Safety and Policy Manager, Nuclear Electric Ltd. For services to Engineering Management. Walter Herbert Love. For services to Radio Journalism. Maurice Ernest Lowe, Engineering Manager, Vosper Thornycroft (UK) Ltd. For services to the Defence Industry. William Lowe. For services to the Library Service. June Valerie Lucas. For services to the community in Stanford Rivers, Essex. Brenda Germaine Lynn, Sub Divisional Officer, Special Constabulary, West Yorkshire Police. For services to the Police. Monica Lynskey, lately Administrative Officer, Office for Standards in Education. James Archibald MacDonald, Head Greenkeeper, Royal Lytham & St Annes Golf Club. For services to Golf. Thomas MacDougall, Retained Sub-Officer, Tayside Fire Brigade. For services to the Fire Service. Williamina MacGregor, School Cook, Lochardil Primary School, Inverness. For services to Education. Jean Macinnes. For services to the Citizens' Advice Bureau in Aberdeen. Laurence Macintyre, Chief Superintendent, Strathclyde Police. For services to the Police. John Kenneth MacKay, Crofter. For services to the community in Sutherlandshire. John Watson Mackay, Head of Recreation and Access Branch, Research and Advisory Services, Directorate, Scottish Natural Heritage. For services to Countryside Recreation. Florence King MacKenzie, Director, Scottish Churches Architectural Heritage Trust. For services to the Restoration of Church Buildings. George MacLean, lately Manager, Air Traffic Service, Sumburgh Airport (Shetland), Civil Aviation Authority.
Kiggans announced on April 12, 2021, that she was running for Virginia's 2nd congressional district to challenge Democratic incumbent Elaine Luria in the 2022 election. Virginia's 2nd district—redrawn after the 2020 census—contains Chesapeake, the Eastern Shore, Isle of Wight, Southampton County, Suffolk County, and Virginia Beach. Kiggans secured her party's nomination on June 21, 2022, after defeating Jarome Bell in the Republican primary with 56% of the vote. She campaigned on issues regarding the economy and inflation, as well as transgenderism and the parental rights movement. The Cook Political Report rated the election as a "tossup" by November 7, 2022. Kiggans defeated Luria in the November general election—a race viewed as critical for the Republican Party to regain its House majority in the 2022 midterms.
De novo gene birth is the process by which new genes evolve from non-coding DNA. De novo genes represent a subset of novel genes, and may be protein-coding or instead act as RNA genes. The processes that govern de novo gene birth are not well understood, although several models exist that describe possible mechanisms by which de novo gene birth may occur. Ancient de novo gene birth events are difficult to detect. Most studies of de novo genes to date have thus focused on young genes, typically taxonomically restricted genes (TRGs) that are present in a single species or lineage, including so-called orphan genes, defined as genes that lack any identifiable homolog. Not all orphan genes arise de novo, but rather through fairly well characterized mechanisms such as gene duplication (including retroposition) or horizontal gene transfer followed by sequence divergence, or by gene fission/fusion. Although de novo gene birth was once viewed as a highly unlikely occurrence, thousands of examples have now been described, and some researchers speculate that de novo gene birth could play a major role in evolutionary innovation, morphological specification, and adaptation, probably promoted by their low level of pleiotropy. Conversely, criticism of the methodology and interpretation used to identify de novo gene candidates has appeared in the literature, including arguments that some reported cases may reflect artefacts of homology detection and annotation rather than genuine novelty.
=== Acute pain === The beak is a complex, functional organ with an extensive nervous supply including nociceptors that sense pain and noxious stimuli. These would almost certainly be stimulated during beak trimming, indicating strongly that acute pain would be experienced. Behavioural evidence of pain after beak trimming in layer hen chicks has been based on the observed reduction in pecking behavior, reduced activity and social behavior, and increased sleep duration. In Japanese quail, beak-trimming by cauterization caused lower body weights and feed intake in the period just after beak trimming. Beak trimmed Muscovy ducks spent less time engaging in beak-related behaviours (preening, feeding, drinking, exploratory pecking) and more time resting than non-trimmed ducks in the days immediately post-trim. These differences disappeared by 1 week post-trim. At 1 week post-trim the trimmed ducks weighed less than non-trimmed ducks, but this difference disappeared by 2 weeks post-trim. It is, however, unclear if the above changes in behaviour arise from pain or from a loss of sensitivity in the beak. Pecking force has been found to decrease after beak trimming in adult hens, possibly indicating that hens are protecting a painful area from further stimulation. However, pecking force did not differ between chicks with or without minor beak-trims at 2 to 9 days of age, suggesting that chicks with minor beak-trims do not experience pain from the beak.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.